Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 6

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1

Key factors in experimental mouse hematopoietic stem cell transplantation

100%
Nevozhay D., Opolski A.
Archivum Immunologiae et Therapiae Experimentalis
|
2006
|
vol. 54
|
issue 4
253-269
EN
The first mouse model of hematopoietic stem cell transplantation (HSCT) was developed more than 50 years ago. HSCT is currently being widely used in a broad range of research areas, which include studies of the engraftment process, the pathogenesis of graft-versus-host disease and possible ways of its treatment and prophylaxis, attempts to use the graft-versus-leukemia/tumor effect in treating hematological and oncological malignancies, cancer vaccine development, induction of transplanted organ tolerance, and gene therapy. However, although this model is widely distributed, many laboratories use different protocols for the procedure. There are a number of papers discussing different HSCT protocols in clinical work, but no articles summarizing mouse laboratory models are available. This review attempts to bring together different details about HSCT in the mouse model, such as the types of transplantation, possible pretreatment regimens and their combinations, methods and sources of graft harvesting and preparation for the transplantation procedure, the influence of graft cell dose and content on the engraftment process, the transplantation method itself, possible complications, symptoms and techniques of their prophylaxis or treatment, as well as follow-up and engraftment assessment. We have also tried to reflect current knowledge of the biology of the engraftment.
2

The role of copper in tumor angiogenesis ? clinical implications

100%
Nasulewicz A., Opolski A.
Postępy Higieny i Medycyny Doświadczalnej
|
2002
|
vol. 56
|
issue 6
691-705
EN
This review concerns a brief introduction into the basics of tumor blood vessels development as well as the regulatory mechanisms of this process. The role of copper ions in tumor angiogenesis is discussed. The new antiangiogenic therapies based on a reduction of copper levels in tumor microenvironment are reviewed.
3

Inhibitors of neoangiogenesis in antitumor therapy

100%
Opolski A., Wietrzyk J.
Postępy Higieny i Medycyny Doświadczalnej
|
2001
|
vol. 55
|
issue 3
369-385
EN
The role of angiogenesis in tumor growth and metastasis is discussed. The endogenous activators and inhibitors of tumor angiogenesis are presented and their mechanisms of action are reviewed. An overview on angiogenesis as a new potential targed of antitumor therapy is described. The clinical trials of various antiangiogenic agents are briefly summarized and their differential mechanisms of action are discussed.
4

The biological activity of synthetic analogs of the laminin active sequences: YIGSR, RGD, SIKVAV

100%
Hill-Bator A., Opolski A.
Postępy Higieny i Medycyny Doświadczalnej
|
2002
|
vol. 56
|
issue 5
579-588
EN
The invasion of malignant cells through the basement membrane is a critical step in local infiltration and metastasis. Adhesion and invasion of malignant cells may be modulated by their receptor mediated binding to the basement membrane glycoprotein laminin. Laminin consists of the sequences with anticancer and antimetastatic activity. Its peptide fragment YIGSR is known to inhibit experimental metastases of several tumors. This sequence and a tripeptide RGD of laminin inhibits both angiogenesis and tumor growth. In contrary, the sequence SIKVAV initiates angiogenesis and tumor progression. Moreover, laminin plays also other functions in human organism. One of them is influence on platelet aggregation and trombegenesis.
5

The role of GABA-ergic system in carcinogenesis

81%
Szczaurska K., Mazurkiewicz M., Opolski A.
Postępy Higieny i Medycyny Doświadczalnej
|
2003
|
vol. 57
|
issue 5
485-500
EN
The gamma-aminobutyric acid (GABA) is the major and the best known neurotransmitter with inhibitory properties in the central nervous system (CNS). Outside the CNS GABA acts as a regulator of muscle tension and controls the secretion of hormones. In the peripheral region, as in the CNS GABA?s function is known to be mediated by GABAA and GABAB receptors. Several recent reports have suggested a relationship between the GABA-ergic system and oncogenesis. It has been confirmed that both GABA content and GAD activity are increased in material from colon, breast, digestive tract, and ovarian cancer. In the light of theory of dynamic balance between stimulating and inhibitory amino acids, disturbances in GABA metabolism may be a sign of the cell?s defensive reaction during carcinogenesis.
6

Novel Ru(III), Rh(III), Pd(II) and Pt(II) complexes with ligands incorporating azole and pyrimidine rings. I. Antiproliferative activity in vitro

81%
Wisniewski M. Z., Wietrzyk J., Opolski A.
|
|
vol. 48
|
issue 1
51-55
EN
A number of co-ordination compounds of Ru(III), Rh(III), Pd(II) and Pt(II) with ligands incorporating azole and pyrimidine rings has been synthesized. The in vitro cell proliferation-inhibitory activity of these compounds was examined against human cancer cell lines: A 549 (lung carcinoma), LS-180 (colon cancer) and MCF-7 (breast cancer), using SRB technique. Six out of 13 compounds studied revealed cytotoxic activity in vitro. Inhibitory dose 50% (ID50) was lower than 4 g/ml, which is an activity criterion accepted in conventional in vitro cytotoxic screening tests. Two compounds revealed weak cytotoxic activity with ID50 higher than 4 g/ml and five compounds were inactive.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.